Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
暂无分享,去创建一个
Nish Chaturvedi | Akshay S. Desai | Marc A Pfeffer | S. Solomon | M. Pfeffer | A. Desai | J. McMurray | B. Brenner | H. Parving | N. Chaturvedi | D. de Zeeuw | F. Persson | S. Haffner | Scott D Solomon | Hans-Henrik Parving | Dick de Zeeuw | Barry M Brenner | John J V McMurray | Steven M Haffner | Frederik Persson | Akshay S Desai | Maria Nicolaides | Alexia Richard | Zhihua Xiang | Patrick Brunel | P. Brunel | M. Nicolaides | A. Richard | Zhihua Xiang
[1] Akshay S. Desai,et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] S. Yusuf,et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. , 2011, European heart journal.
[3] T. Berl,et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. , 2011, European heart journal.
[4] Akshay S. Desai,et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. , 2011, European heart journal.
[5] Vilmundur Gudnason,et al. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .
[6] Henry Krum,et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study , 2011, European journal of heart failure.
[7] M. Gheorghiade,et al. Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) , 2011, European journal of heart failure.
[8] S. Solomon,et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). , 2010, Journal of cardiac failure.
[9] B. Brenner,et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial , 2010, Diabetologia.
[10] M. Woodward,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.
[11] M. Pfeffer,et al. Can there be any surrogate for safety , 2010 .
[12] S. Solomon,et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] M. Pfeffer,et al. Leapfrogging data: no shortcuts for safety or efficacy information. , 2008, Circulation.
[14] Rury R Holman,et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. , 2008, The New England journal of medicine.
[15] Tom Greene,et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (Annals of Internal Medicine (2006) 145, (247-254)) , 2008 .
[16] S. Yusuf,et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.
[17] E. Lewis,et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.
[18] S. Solomon,et al. Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.
[19] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[20] S. Oparil,et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial , 2007, The Lancet.
[21] Yuliya Lokhnygina,et al. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. , 2007, European heart journal.
[22] J. Staessen,et al. Oral renin inhibitors , 2006, The Lancet.
[23] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[24] S. Yusuf,et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.
[25] H. Parving,et al. Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate , 2004, Diabetologia.
[26] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[27] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[28] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[29] N. Hollenberg,et al. Literature alert , 2002 .
[30] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[31] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[32] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[33] Salim Yusuf,et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.
[34] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[35] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[36] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[37] G. Remuzzi,et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.
[38] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.